Last reviewed · How we verify

Corporacion Parc Tauli — Portfolio Competitive Intelligence Brief

Corporacion Parc Tauli pipeline: 3 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Hydrochlorothiazide and furosemide Hydrochlorothiazide and furosemide marketed
Bupivacaine 7 mg Bupivacaine 7 mg marketed
fentanyl 15 microg fentanyl 15 microg marketed Opioid agonist Mu-opioid receptor (OPRM1) Pain Management
L-BUPIVACAINE ; MORPHINE L-BUPIVACAINE ; MORPHINE phase 3 Local anesthetic + opioid analgesic combination Voltage-gated sodium channels (L-bupivacaine); mu-opioid receptor (morphine) Anesthesia and Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aga Khan University · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  4. Beijing Friendship Hospital · 1 shared drug class
  5. Cephalon · 1 shared drug class
  6. Ciusss de L'Est de l'Île de Montréal · 1 shared drug class
  7. Conrad Arnfinn Bjørshol · 1 shared drug class
  8. Aarhus University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Corporacion Parc Tauli:

Cite this brief

Drug Landscape (2026). Corporacion Parc Tauli — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/corporacion-parc-tauli. Accessed 2026-05-16.

Related